Hillerich, Vivienne
Valbert, Frederik
Neusser, Silke
Pfaar, Oliver
Klimek, Ludger
Sperl, Annette
Werfel, Thomas
Hamelmann, Eckard
Riederer, Cordula
Wobbe-Ribinski, Stefanie
Neumann, Anja
Wasem, Jürgen
Biermann-Stallwitz, Janine
Funding for this research was provided by:
innovation fund (fund of the federal joint committee, “gemeinsamer bundesausschuss”)innovation fund (01VSF17042)
Universität Duisburg-Essen
Article History
Received: 19 July 2021
Accepted: 17 May 2023
First Online: 7 July 2023
Declarations
:
: Dr. Klimek reports grants and personal fees from Allergopharma, grants and personal fees from MEDA/Mylan, personal fees from HAL Allergie, grants from ALK Abelló, grants and personal fees from LETI Pharma, grants from Stallergenes, grants from Quintiles, grants and personal fees from Sanofi, grants from ASIT biotech, grants from Lofarma, personal fees from Allergy Therapeut., grants from AstraZeneca, grants from GSK, grants from Inmunotk, personal fees from Cassella med, outside the submitted work; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO-BV, GPA, EAACI. Dr. Pfaar reports grants and personal fees from ALK-Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from MEDA Pharma/MYLAN, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Indoor Biotechnologies, grants and personal fees from GlaxoSmithKline, personal fees from Astellas Pharma Global, personal fees from EUFOREA, personal fees from ROXALL Medizin, personal fees from Novartis, personal fees from Sanofi-Aventis and Sanofi-Genzyme, personal fees from Med Update Europe GmbH, personal fees from streamedup! GmbH, grants from Pohl-Boskamp, grants from Inmunotek S.L., personal fees from John Wiley and Sons, AS, personal fees from Paul-Martini-Stiftung (PMS), personal fees from Ingress-Health HWM, personal fees from Regeneron Pharmaceuticals Inc., outside the submitted work. The remaining authors have no conflicts of interest to declare.
: The study was registered in the German Clinical Trials Register (DRKS) (DRKS00017316) and an ethic approval has been obtained from the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen (19–8598-BO).
: Only patients with valid written informed consent were included. Non-participation was not associated with any disadvantages for the patient.
: Not applicable (only aggregated data is published, which does not allow any conclusions to be drawn about individuals).